Mingyu Liang, MB, PhD
Professor and Kohler Co. Chair in Physiology; Director, Center of Systems Molecular Medicine; Vice-Chair for Interdisciplinary and Translational Research
Postdoctoral Fellow, Nephrology, Mayo Clinic and Foundation, 2000
Postdoctoral Fellow, Physiology, Medical College of Wisconsin, 2002
MB - Medicine, Shanghai Medical University, 1994
Honors and Awards
2017: Distinguished Lectureship in Physiological Genomics Research, American Physiological Society
2015-2020: Center Director, American Heart Association Strategically Focused Hypertension Research Center (including basic, clinical and population research)
2012: Henry Pickering Bowditch Award, American Physiological Society
2009: Outstanding Teacher of the Year, MCW Graduate School
1994: Outstanding Graduate, Shanghai Municipality
Associate Editor: Physiol Genomics (2007-2015); Compr Physiol (2017-present)
Editorial board: J Am Soc Nephrol; Hypertension
I am a molecular systems medicine researcher. The current work in my laboratory focuses on three areas: (epi)genomics and precision medicine, regulatory RNA, and cellular metabolism, as they relate to hypertension and cardiovascular and kidney diseases. We have a translational, multidisciplinary, and programmatic research platform in our laboratory where we integrate human research with research in animals, human induced pluripotent stem cells (iPSC), and other model systems using approaches of physiology, genetics, biochemistry, molecular biology, genome editing, and big data analysis.
For a complete list of our laboratory’s publications since 2002, search PubMed for “Mingyu Liang”.
Research Area 1: (Epi)genomics and precision medicine
We develop innovative approaches to precision medicine for common cardiovascular and renal diseases with a particular focus on the incorporation of tissue functional genomic analysis. We study molecular regulatory networks, including genomic and epigenomic mechanisms, underlying physiology and disease.
1. Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M. Histologically resolved small RNA maps in primary focal segmental glomerulosclerosis indicate progressive changes within glomerular and tubulointerstitial regions. Kidney Int. 2022. Online ahead of print.
2. Mishra MK, Liang EY, Geurts AM, Auer PWL, Liu P, Rao S, Greene AS, Liang M, Liu Y. Comparative and Functional Genomic Resource for Mechanistic Studies of Human Blood Pressure-Associated Single Nucleotide Polymorphisms. Hypertension 2020; 75: 859-868.
3. Baker MA, Davis SJ, Liu P, Pan X, Williams AM, Iczkowski KA, Gallagher ST, Bishop K, Regner KR, Liu Y, Liang M. Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease. J Am Soc Nephrol. 2017; 28: 2985-2992.
4. Kotchen TA, Cowley AW Jr, Liang M. Ushering hypertension into the new era of precision medicine. JAMA 2016; 315: 343-4.
Research Area 2: Regulatory RNA
The general significance of microRNAs in the regulation of gene expression, cellular function, and disease development is widely recognized. However, the specific role of many microRNAs, and other regulatory RNA such as long non-coding RNA, in physiological and disease processes remain unknown. Our laboratory investigates the role of regulatory RNA in hypertension and cardiovascular and renal injury in humans and model systems.
1. Cheng Y, Wang D, Wang F, Liu J, Huang B, Baker MA, Yin J, Wu R, Liu X, Regner KR, Usa K, Liu Y, Zhang C, Dong L, Geurts AM, Wang N, Miller SS, He Y, Liang M. Endogenous miR-204 protects the kidney against chronic injury in hypertension and diabetes. J Am Soc Nephrol. 2020; 31: 1539-1554.
2. Widlansky ME, Jensen DM, Wang J, Liu Y, Geurts AM, Kriegel AJ, Liu P, Ying R, Zhang G, Casati M, Chu C, Malik M, Branum A, Tanner MJ, Tyagi S, Usa K, Liang M. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol Med 2018; e8046.
3. Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase β1. Nucleic Acids Res. 2013; 41: 1273-83.
4. Xu X, Kriegel AJ, Liu Y, Usa K, Mladinov D, Liu H, Fang Y, Ding X, Liang M. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int. 2012; 82: 1167-75.
5. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC, and Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010; 55: 974-82.
6. Tian Z, Greene AS, Pietrusz JL, Matus IR, and Liang M. microRNA-target pairs in rat kidneys identified through microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008; 18: 404-411.
Research Area 3: Cellular metabolism
Our laboratory routinely combines exploratory approaches and hypothesis-driven approaches to discover novel disease mechanisms in humans and animal models. Recent discoveries that we are exploring in depth include novel roles of abnormalities in cellular metabolism in the development of hypertension and tissue injury.
1. Tian Z, Liang M. Renal Metabolism and Hypertension. Nat Commun. 2021; 12: 963.
2. Cheng Y, Song H, Pan X, Xue H, Wan Y, Wang T, Tian Z, Hou E, Lanza IR, Liu P, Liu Y, Laud PW, Usa K, He Y, Liang M. Urinary Metabolites Associated with Blood Pressure on a Low- or High-Sodium Diet. Theranostics 2018; 8: 1468-1480.
3. Hou E, Sun N, Zhang F, Zhao C, Usa K, Liang M, Tian Z. Malate and Aspartate Increase L-arginine and Nitric Oxide and Attenuate Hypertension. Cell Rep. 2017; 19: 1631-1639.
4. Tian Z, Liu Y, Usa K, Mladinov D, Fang Y, Ding X, Greene AS, Cowley AW Jr, Liang M. Novel Role of Fumarate Metabolism in Dahl Salt-Sensitive Hypertension. Hypertension 2009; 54: 255-60.
Please contact Dr. Liang if you are interested in a post-doctoral fellow or pre-doctoral student position in his laboratory.
(Williams AM, Jensen DM, Pan X, Liu P, Liu J, Huls S, Regner KR, Iczkowski KA, Wang F, Li J, Gallan AJ, Wang T, Baker MA, Liu Y, Lalehzari N, Liang M.) Kidney Int. 2022 Apr;101(4):766-778 PMID: 35114200 PMCID: PMC8940673 SCOPUS ID: 2-s2.0-85125312317 02/04/2022
(Roberts ML, Kotchen TA, Pan X, Li Y, Yang C, Liu P, Wang T, Laud PW, Chelius TH, Munyura Y, Mattson DL, Liu Y, Cowley AW Jr, Kidambi S, Liang M.) Hypertension. 2022 Apr;79(4):761-772 PMID: 34994206 PMCID: PMC8917053 SCOPUS ID: 2-s2.0-85126152389 01/08/2022
(Tomar N, Zhang X, Kandel SM, Sadri S, Yang C, Liang M, Audi SH, Cowley AW Jr, Dash RK.) Biochim Biophys Acta Bioenerg. 2022 Feb 01;1863(2):148518 PMID: 34864090 PMCID: PMC8957717 SCOPUS ID: 2-s2.0-85120828118 12/06/2021
(Cowley AW Jr, Kidambi S, Liang M, Grim C, Hamet P.) Hypertension. 2021 Dec;78(6):1674-1676 PMID: 34719936 SCOPUS ID: 2-s2.0-85121955751 11/02/2021
(Liu J, Liu Y, Wang F, Liang M.) Hypertension. 2021 Aug;78(2):270-281 PMID: 34176282 PMCID: PMC8283800 SCOPUS ID: 2-s2.0-85109560313 06/29/2021
(Kidambi S, Pan X, Yang C, Liu P, Roberts ML, Li Y, Wang T, Laud PW, Liu Y, Rubens M, Thomas R, Widlansky ME, Beyer AM, Liu Y, Cowley AW Jr, Kotchen TA, Munyura Y, Moosreiner A, Mattson DL, Liang M.) Hypertension. 2021 Aug;78(2):434-446 PMID: 34120454 PMCID: PMC9299531 SCOPUS ID: 2-s2.0-85109563974 06/15/2021
(Santillan MK, Becker RC, Calhoun DA, Cowley AW, Flynn JT, Grobe JL, Kotchen TA, Lackland DT, Leslie KK, Liang M, Mattson DL, Meyers KE, Mitsnefes MM, Muntner PM, Pierce GL, Pollock JS, Sigmund CD, Thomas SJ, Urbina EM, Kidambi S.) Hypertension. 2021 Jun;77(6):1857-1866 PMID: 33934625 PMCID: PMC8986150 SCOPUS ID: 2-s2.0-85105820455 05/04/2021
(Pan X, Geng X, Liu Y, Yu M, Mishra MK, Xu X, Ding X, Liu P, Liang M.) Hypertension. 2021 May 05;77(5):1627-1637 PMID: 33775129 PMCID: PMC8370717 SCOPUS ID: 2-s2.0-85104047516 03/30/2021
(Perry TR, Roberts ML, Sunkara B, Maddula R, McLeish T, Gomez J, Lucas J, Rayan D, Patel S, Liang M, Bosnjak ZJ, Brown SA.) Curr Oncol Rep. 2021 May 03;23(7):77 PMID: 33937943 PMCID: PMC8088904 SCOPUS ID: 2-s2.0-85105159465 05/04/2021
(Tian Z, Liang M.) Nat Commun. 2021 Feb 11;12(1):963 PMID: 33574248 PMCID: PMC7878744 SCOPUS ID: 2-s2.0-85101144154 02/13/2021
(Sun X, Yi J, Yang J, Han Y, Qian X, Liu Y, Li J, Lu B, Zhang J, Pan X, Liu Y, Liang M, Chen E, Liu P, Lu Y.) Theranostics. 11 March 2021;11(11):5346-5364 SCOPUS ID: 2-s2.0-85102449346 03/11/2021
(Williams AM, Liang M.) Kidney Int. 2020 Aug;98(2):275-277 PMID: 32709285 SCOPUS ID: 2-s2.0-85087919832 07/28/2020